Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q1 2022 · 10-Q
Revenue$74.00K$74.00K+2.8% vs Q1 2021 Net Income-$10.99M-$10.99MN/M vs Q1 2021 EPS Diluted-$0.25-$0.25N/M vs Q1 2021 Operating Income-$11,074,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
Free Cash Flowderived-$10,420,000N/M Margins · derivedOperating margin-14964.9%−7406.5 pt vs Q1 2021
Net margin-14855.4%−7662.3 pt vs Q1 2021
ended Mar 31, 2022 · filed May 5, 2022 · 35 d after period end